Johnson & Johnson launches heparin-coated stent in US:
This article was originally published in Clinica
Executive Summary
Johnson & Johnson's Cordis subsidiary has begun a limited US launch of what it claims is the first drug-coated stent using heparin to gain approval in US and Europe, the Bx Velocity coronary stent with Hepacoat. The product received European approval in June and in the US in July. The company plans a full roll-out of the product in the first and second quarters of next year. The stent is coated with Carmeda's Bioactive surface, which retains thromboresistant properties for several months.